Journal
ANNUAL REVIEW OF NEUROSCIENCE, VOL 41
Volume 41, Issue -, Pages 1-23Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-neuro-080317-061747
Keywords
mTOR; autism; tuberous sclerosis; PTEN; rapamycin; fragile X
Categories
Funding
- EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD090255] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS092595, R25NS070682, U01NS082320] Funding Source: NIH RePORTER
- NICHD NIH HHS [U54 HD090255] Funding Source: Medline
- NINDS NIH HHS [R25 NS070682, U01 NS092595, U01 NS082320] Funding Source: Medline
Ask authors/readers for more resources
The mechanistic target of rapamycin (mTOR) is an important signaling hub that integrates environmental information regarding energy availability and stimulates anabolic molecular processes and cell growth. Abnormalities in this pathway have been identified in several syndromes in which autism spectrum disorder (ASD) is highly prevalent. Several studies have investigated mTOR signaling in developmental and neuronal processes that, when dysregulated, could contribute to the development of ASD. Although many potential mechanisms still remain to be fully understood, these associations are of great interest because of the clinical availability of mTOR inhibitors. Clinical trials evaluating the efficacy of mTOR inhibitors to improve neurodevelopmental outcomes have been initiated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available